We are live on ! Find out more
BLPH

Bellerophon Therapeutics, Inc.

Delisted

BLPH was delisted on the 13th of October, 2023.

30 hedge funds and large institutions have $37.4M invested in Bellerophon Therapeutics, Inc. in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

3% more funds holding

Funds holding: 2930 (+1)

54% less capital invested

Capital invested by funds: $81.8M → $37.4M (-$44.4M)

Holders
30
Holders Change
+1
Holders Change %
+3.45%
% of All Funds
0.69%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
7
Increased
8
Reduced
4
Closed
6
Calls
Puts
Net Calls
Net Calls Change

BLPH Hedge Fund Activity: Q3 2018 in Review

30 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q3 2018, worth a combined $37.4M — down 54% from $81.8M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new BLPH positions and 6 closed out — a net gain of 1 holder — while 8 added to existing stakes and 4 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $85.7K. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.57M sold.

  • 30 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q3 2018, up from 29 in Q2 2018.
  • Funds reported $37.4M of Bellerophon Therapeutics, Inc. stock for Q3 2018, down 54% quarter-over-quarter.
  • 7 funds opened new Bellerophon Therapeutics, Inc. positions in Q3 2018 and 6 closed out, a net change of +1 holder.
  • The largest Bellerophon Therapeutics, Inc. buyer in Q3 2018 was Renaissance Technologies, an estimated $85.7K added.
  • The largest Bellerophon Therapeutics, Inc. seller in Q3 2018 was Fidelity Investments, an estimated $1.57M sold.

Based on aggregated 13F filings for Q3 2018.